Tedizolid

Tedizolid
Clinical data
Trade names	Sivextro
Other names	TR-700, torezolid
AHFS/Drugs.com	Monograph
MedlinePlus	a614038
License data	US DailyMed: Tedizolid;
Routes of; administration	By mouth, intravenous
ATC code	J01XX11 (WHO) ;
Legal status
Legal status	CA: ℞-only; US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Bioavailability	91%
Protein binding	70–90%
Elimination half-life	12 hours
Excretion	Feces
Identifiers
	IUPAC name (5R)-3-{3-fluoro-4-[6-(2-methyl-2H-tetrazol-5-yl)pyridin-3-yl]phenyl}-5-(hydroxymethyl)-1,3-oxazolidin-2-one;
CAS Number	856866-72-3 ; Phosphate: 856867-55-5 ;
PubChem CID	11234049;
DrugBank	DB09042 ;
ChemSpider	9409096 ;
UNII	97HLQ82NGL; Phosphate: O7DRJ6R4DW ;
KEGG	D09685 ; Phosphate: D09686 ;
ChEBI	CHEBI:82717 ;
ChEMBL	ChEMBL1257051 ;
CompTox Dashboard (EPA)	DTXSID10234975 ;
ECHA InfoCard	100.249.430
Chemical and physical data
Formula	C17H15FN6O3
Molar mass	370.344 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C4O[C@H](CN4c3cc(F)c(c1ccc(nc1)c2nn(nn2)C)cc3)CO;
	InChI InChI=1S/C17H15FN6O3/c1-23-21-16(20-22-23)15-5-2-10(7-19-15)13-4-3-11(6-14(13)18)24-8-12(9-25)27-17(24)26/h2-7,12,25H,8-9H2,1H3/t12-/m1/s1 ; Key:XFALPSLJIHVRKE-GFCCVEGCSA-N ;
	(what is this?) (verify)

Tedizolid, sold under the brand name Sivextro (by Merck) is an oxazolidinone-class antibiotic. Tedizolid phosphate is a phosphate ester prodrug of the active compound tedizolid. It was developed by Cubist Pharmaceuticals, following acquisition of Trius Therapeutics (originator: Dong-A Pharmaceuticals), and is marketed for the treatment of acute bacterial skin and skin structure infections (also known as complicated skin and skin-structure infections (cSSSIs)).^[5]

The most common side effects include nausea (feeling sick), headache, diarrhoea and vomiting.^[4] These side effects were generally of mild or moderate severity.^[4]

Tedizolid was approved for medical use by the FDA in the United States in June 2014,^[6]^[7] and for medical use in the European Union by EMA in March 2015.^[4]

^ "Trius grows as lead antibiotic moves forward". 31 Oct 2011.
^ "Health Canada New Drug Authorizations: 2015 Highlights". Health Canada. 4 May 2016. Retrieved 7 April 2024.
^ Cite error: The named reference Sivextro FDA label was invoked but never defined (see the help page).
^ ^a ^b ^c ^d Cite error: The named reference Sivextro EPAR was invoked but never defined (see the help page).
^ "Cubist Pharmaceuticals to Acquire Trius Therapeutics". July 2013. Archived from the original on 2015-04-02. Retrieved 2015-03-17.
^ Cite error: The named reference FDA approval tablets was invoked but never defined (see the help page).
^ Cite error: The named reference FDA approval injection was invoked but never defined (see the help page).

[Nov2011-1] "Trius grows as lead antibiotic moves forward". 31 Oct 2011.

[2] "Health Canada New Drug Authorizations: 2015 Highlights". Health Canada. 4 May 2016. Retrieved 7 April 2024.

[Sivextro_FDA_label-3] Cite error: The named reference Sivextro FDA label was invoked but never defined (see the help page).

[Sivextro_EPAR-4] Cite error: The named reference Sivextro EPAR was invoked but never defined (see the help page).

[5] "Cubist Pharmaceuticals to Acquire Trius Therapeutics". July 2013. Archived from the original on 2015-04-02. Retrieved 2015-03-17.

[FDA_approval_tablets-6] Cite error: The named reference FDA approval tablets was invoked but never defined (see the help page).

[FDA_approval_injection-7] Cite error: The named reference FDA approval injection was invoked but never defined (see the help page).

[1]

[2]

[3]

[4]

[5]

[6]

[7]